Kawasaki N, Nishito Y, Yoshimura Y, Yoshiura S, et al. The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma. Br J Haematol 2022 Jun 28. doi: 10.1111/bjh.18341.
PMID: 35764309